Interleukin‐2 diphtheria fusion protein (dab₄₈₆il‐2) in refractory rheumatoid arthritis a double‐blind, placebo‐controlled trial with open‐label extension

Abstract

Clinical responses were noted in patients treated with DAB486IL-2 (18%) compared with placebo (0%) in the double-blind phase. In the open-label phase, 33% of patients completing 3 monthly DAB486IL-2 cycles had improvement in arthritis activity. Further studies of IL-2 diphtheria fusion proteins are warranted to elucidate factors that may predict clinical response and define mechanism(s) of action.